Influence of Different Surgical Procedure on Prognosis of Elderly Patients with Stage Ⅰ Non-small Cell Lung Cancer_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

RENQing-quan

Department of Thoracic Surgery in Yanan University Affiliated Hospital, Yanan 716000, P. R. China;

Corresponding author：

Keywords：

Non-small cell lung cancer; Elderly patients; Prognosis

DOI：

10.7507/1007-4848.20150236

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the influence of different surgical procedure on the prognosis of elderly patients with stage Ⅰ non-small cell lung cancer (NSCLC). Methods We retrospectively analyzed the clinical data of 100 patients elder than 70 years with NSCLC in our hospital between January 2012 and December 2013. There were 60 males and 40 females patients at age of 70-85 (76±12) years. The patients were divided into two groups including a standard lobectomy group (62 patients, receiving standard lobectomy) and a limited resection group (38 patients receiving limited resection). Regular following-up was carried out after the surgery. The correlation between the survival rate and the incidences of complications, the surgical procedure were analyzed. Results The incidence of complications in the standard lobectomy group and the limited resection group was 35.5%(22/62)and 39.5%(15/38)respectively. The three year survival rate and the five year survival rate in the two groups were similar between the two groups(85.5% versus 54.8% and 78.9% versus 55.3%). There was no statistical difference between the two groups. Staging is an independent factor for prognosis. Conclusion Lobectomy is still the main therapy method for elderly stageⅠNSCLC patients. But limited resection also appears to be a viable surgical treatment for patients with cardiopulmonary physiologic impairment.

Citation： RENQing-quan. Influence of Different Surgical Procedure on Prognosis of Elderly Patients with Stage Ⅰ Non-small Cell Lung Cancer. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2015, 22(10): 944-947. doi: 10.7507/1007-4848.20150236 Copy

1.	Chang A.Chemotherapy,chemoresistance and the changing treatment landscape for NSCLC.Lung cancer,2011,71(1):3-10.
2.	Ramalingam SS,Owonikoko TK,Khuri FR.Lung cancer:new biological insights and recent therapeutic advances.CA:Can J Clin,2011,61(2):91-112.
3.	Chen YM,Tsai CM,Fan WC,et al.Phase Ⅱ randomized trial of erlotinib or vinorelbine in chemonaive,advanced,non-small cell lung cancer patients aged 70 years or older.J Thorac Oncol,2012,7(2):412-418.
4.	Stinchcombe TE,Peterman AH,Lee CB,et al.A randomized phase Ⅱ trial of first-line treatment with gemcitabine,erlotinib,or gemcitabine and erlotinib in elderly patients(age ≥ 70 years)with stage ⅢB/IV non-small cell lung cancer.J Thorac Oncol,2011,6(9):1569-1577.
5.	Stinchcombe TE,Peterman AH,Lee CB,et al.A randomized phase Ⅱ trial of first-line treatment with gemcitabine,erlotinib,or gemcitabine and erlotinib in elderly patients(age ≥ 70 years)with stage ⅢB/IV non-small cell lung cancer.J Thorac Oncol,2011,6(9):1569-1577.
6.	Bauml J,Mick R,Zhang Y,et al.Determinants of survival in advanced non-small-cell lung cancer in the era of targeted therapies.Clin Lung Cancer,2013,14(5):581-591.
7.	Nasir BS,Bryant AS,Douglas J,et al.The efficacy of restaging endobronchial ultrasound in patients with non-small cell lung cancer after preoperative therapy.Ann Thorac Surg,2014,98(3):1008-1012.
8.	Donington JS,Pass HI.Surgical resection of non-small cell lung cancer with N2 disease.Thorac Surg Clin,2014,24(4):449-456.
9.	Kratz JR,Van Den Eeden SK,He J,et al.A prognostic assay to identify patients at high risk of mortality despite small,nodenegative lung tumors.JAMA,2012,308(16):1629-1631.
10.	Sigel K,Lurslurchachai L,Bonomi M,et al.Effectiveness of radiation therapy alone for elderly patients with unresected stage Ⅲ non-small cell lung.Lung Cancer,2013,82(2):266-270.
11.	Powell HA,Tata LJ,Baldwin DR,et al.Early mortality after surgical resection for lung cancer:an analysis of the English National Lung cancer audit.Thorax,2013,68(9):826-834.
12.	Wei L,Liu X,Hu C.Correlation between expression of HIF-2α and OCT-4 and prognosis of NSCLC.Med Sciences,2011,36(9):854-858.
13.	Hu Y,Hu MM,Shi GL,et al.Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.Euro J Surg Oncol,2014,40(9):1136-1142.
14.	Dai J,Jin G,Dong J,et al.Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival.J Thorac Oncol,2010,5(11):1748-1754.
15.	Ramalingam SS,Owonikoko TK,Khuri FR.Lung cancer:new biological insights and recent therapeutic advances.CA Can J Clin,2011,61(2):91-112.
16.	Wong K,Koczywas M,Goldman JW,et al.An open-label phase Ⅱ study of the Hsp90 inhibitor ganetespib(STA-9090)as monotherapy in patients with advanced non-small cell lung cancer(NSCLC)[C]//ASCO Meeting Abstracts,2011,29(15suppl):7500.
17.	Kates M,Swanson S,Wisnivesky JP.Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer≤1 cm in size:a review of SEER data.Chest,2011,139(3):491-496.
18.	张正华,主编.高龄非小细胞肺癌患者术后生存期的研究.安徽:安徽医科大学,2010.12-24.
19.	Quoix E,Westeel V,Zalcman G,et al.Chemotherapy in elderly patients with advanced non-small cell lung cancer.Lung Cancer,2011,24(3):364-368.
20.	Kim YT,Kang CH,Sung SW,et al.Local control of disease related to lymph node involvement in non-small cell lung cancer after sleeve lobectomy compared with pneumonectomy.Ann Thorac Surg,2005,79(4):1153-1161.
21.	高禹舜,王兵,赫捷.263例老年非小细胞肺癌的外科治疗.中华老年多器官疾病杂志,2009,8(2):104-126.
22.	Katcoff H,Wenzlaff AS,Schwartz AG.Survival in women with nsclc:the role of reproductive history and hormone use.J Thorac Oncol,2014,9(3):355-361.
23.	Cusumano G,Marra A,Lococo F,et al.Is sleeve lobectomy comparable in terms of short-and long-term results with pneumonectomy after induction therapy?a multicenter analysis.Ann Thorac Surg,2014,98(3):975-983.
24.	Pines A.Postmenopausal hormone therapy and lung cancer.Climacteric,2011,14(2):212-214.
25.	Wakelee HA,Dahlberg SE,Brahmer JR,et al.Differential effect of age on survival in advanced NSCLC in women versus men:analysis of recent Eastern Cooperative Oncology Group(ECOG)studies,with and without bevacizumab.Lung Cancer,2012,76(3):410-415.

1. Chang A.Chemotherapy,chemoresistance and the changing treatment landscape for NSCLC.Lung cancer,2011,71(1):3-10.
2. Ramalingam SS,Owonikoko TK,Khuri FR.Lung cancer:new biological insights and recent therapeutic advances.CA:Can J Clin,2011,61(2):91-112.
3. Chen YM,Tsai CM,Fan WC,et al.Phase Ⅱ randomized trial of erlotinib or vinorelbine in chemonaive,advanced,non-small cell lung cancer patients aged 70 years or older.J Thorac Oncol,2012,7(2):412-418.
4. Stinchcombe TE,Peterman AH,Lee CB,et al.A randomized phase Ⅱ trial of first-line treatment with gemcitabine,erlotinib,or gemcitabine and erlotinib in elderly patients(age ≥ 70 years)with stage ⅢB/IV non-small cell lung cancer.J Thorac Oncol,2011,6(9):1569-1577.
5. Stinchcombe TE,Peterman AH,Lee CB,et al.A randomized phase Ⅱ trial of first-line treatment with gemcitabine,erlotinib,or gemcitabine and erlotinib in elderly patients(age ≥ 70 years)with stage ⅢB/IV non-small cell lung cancer.J Thorac Oncol,2011,6(9):1569-1577.
6. Bauml J,Mick R,Zhang Y,et al.Determinants of survival in advanced non-small-cell lung cancer in the era of targeted therapies.Clin Lung Cancer,2013,14(5):581-591.
7. Nasir BS,Bryant AS,Douglas J,et al.The efficacy of restaging endobronchial ultrasound in patients with non-small cell lung cancer after preoperative therapy.Ann Thorac Surg,2014,98(3):1008-1012.
8. Donington JS,Pass HI.Surgical resection of non-small cell lung cancer with N2 disease.Thorac Surg Clin,2014,24(4):449-456.
9. Kratz JR,Van Den Eeden SK,He J,et al.A prognostic assay to identify patients at high risk of mortality despite small,nodenegative lung tumors.JAMA,2012,308(16):1629-1631.
10. Sigel K,Lurslurchachai L,Bonomi M,et al.Effectiveness of radiation therapy alone for elderly patients with unresected stage Ⅲ non-small cell lung.Lung Cancer,2013,82(2):266-270.
11. Powell HA,Tata LJ,Baldwin DR,et al.Early mortality after surgical resection for lung cancer:an analysis of the English National Lung cancer audit.Thorax,2013,68(9):826-834.
12. Wei L,Liu X,Hu C.Correlation between expression of HIF-2α and OCT-4 and prognosis of NSCLC.Med Sciences,2011,36(9):854-858.
13. Hu Y,Hu MM,Shi GL,et al.Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.Euro J Surg Oncol,2014,40(9):1136-1142.
14. Dai J,Jin G,Dong J,et al.Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival.J Thorac Oncol,2010,5(11):1748-1754.
15. Ramalingam SS,Owonikoko TK,Khuri FR.Lung cancer:new biological insights and recent therapeutic advances.CA Can J Clin,2011,61(2):91-112.
16. Wong K,Koczywas M,Goldman JW,et al.An open-label phase Ⅱ study of the Hsp90 inhibitor ganetespib(STA-9090)as monotherapy in patients with advanced non-small cell lung cancer(NSCLC)[C]//ASCO Meeting Abstracts,2011,29(15suppl):7500.
17. Kates M,Swanson S,Wisnivesky JP.Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer≤1 cm in size:a review of SEER data.Chest,2011,139(3):491-496.
18. 张正华,主编.高龄非小细胞肺癌患者术后生存期的研究.安徽:安徽医科大学,2010.12-24.
19. Quoix E,Westeel V,Zalcman G,et al.Chemotherapy in elderly patients with advanced non-small cell lung cancer.Lung Cancer,2011,24(3):364-368.
20. Kim YT,Kang CH,Sung SW,et al.Local control of disease related to lymph node involvement in non-small cell lung cancer after sleeve lobectomy compared with pneumonectomy.Ann Thorac Surg,2005,79(4):1153-1161.
21. 高禹舜,王兵,赫捷.263例老年非小细胞肺癌的外科治疗.中华老年多器官疾病杂志,2009,8(2):104-126.
22. Katcoff H,Wenzlaff AS,Schwartz AG.Survival in women with nsclc:the role of reproductive history and hormone use.J Thorac Oncol,2014,9(3):355-361.
23. Cusumano G,Marra A,Lococo F,et al.Is sleeve lobectomy comparable in terms of short-and long-term results with pneumonectomy after induction therapy?a multicenter analysis.Ann Thorac Surg,2014,98(3):975-983.
24. Pines A.Postmenopausal hormone therapy and lung cancer.Climacteric,2011,14(2):212-214.
25. Wakelee HA,Dahlberg SE,Brahmer JR,et al.Differential effect of age on survival in advanced NSCLC in women versus men:analysis of recent Eastern Cooperative Oncology Group(ECOG)studies,with and without bevacizumab.Lung Cancer,2012,76(3):410-415.

Previous Article
Mediastinal Tumor Resection without Drainage by Da Vinci S Surgical System: A Case Control Study
Next Article
Epidemiology, Etiology and Prognosis of Pneumonia in Lung Transplantation Recipients

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Influence of Different Surgical Procedure on Prognosis of Elderly Patients with Stage Ⅰ Non-small Cell Lung Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content